A Tumor Sorting Protocol that Enables Enrichment of Pancreatic Adenocarcinoma Cells and Facilitation of Genetic Analyses

Yazar: Boyd, Zachary S., Raja, Rajiv, Johnson, Stephanie, Eberhard, David A., Lackner, Mark R.
Baskı/Yayın Bilgisi 2009

Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

Yazar: Sangro, Bruno, Melero, Ignacio, Wadhawan, Samir, Finn, Richard S., Abou-Alfa, Ghassan K., Cheng, Ann-Lii, Yau, Thomas, Furuse, Junji, Park, Joong-Won, Boyd, Zachary, Tang, Hao (Tracy), Shen, Yun, Tschaika, Marina, Neely, Jaclyn, El-Khoueiry, Anthony
Yayımlandı J Hepatol (2020)

Myeloid cell biology and inhibition of anti-tumor immune responses by MPDL3280A in urothelial bladder cancer

Yazar: Xiao, Yuanyuan, Rabe, Christina, Kowanetz, Marcin, Powles, Thomas, Vogelzang, Nicholas J, Petrylak, Daniel P, Loriot, Yohann, Denker, Mitchell, Nakamura, Rin, Wu, Qun J, Sumiyoshi, Teiko, Boyd, Zachary, Teng, Siew-leng M, Shen, Xiaodong, Fine, Gregg, Chen, Daniel S, Hegde, Priti S
Yayımlandı J Immunother Cancer (2014)

Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC)

Yazar: Powles, Thomas, Nickles, Dorothee, Van Allen, Eliezer, Chappey, Colombe, Zou, Wei, Kowanetz, Marcin, Kadel, Edward, Denker, Mitchell, Boyd, Zachary, Vogelzang, Nicholas, Kim, Joseph, Bellmunt, Joaquim, Loriot, Yohann, Drake, Charles G, O'Hear, Carol, Fasso, Marcella, Hegde, Priti, Mariathasan, Sanjeev
Yayımlandı J Immunother Cancer (2015)

Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab

Yazar: Vennapusa, Bharathi, Baker, Brian, Kowanetz, Marcin, Boone, Jennifer, Menzl, Ina, Bruey, Jean-Marie, Fine, Gregg, Mariathasan, Sanjeev, McCaffery, Ian, Mocci, Simonetta, Rost, Sandra, Smith, Dustin, Dennis, Eslie, Tang, Szu-Yu, Damadzadeh, Bita, Walker, Espen, Hegde, Priti S., Williams, J. Andrew, Koeppen, Hartmut, Boyd, Zachary
Yayımlandı Appl Immunohistochem Mol Morphol (2019)

Atezolizumab as first-line therapy in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

Yazar: Balar, Arjun V, Galsky, Matthew D, Rosenberg, Jonathan E, Powles, Thomas, Petrylak, Daniel P, Bellmunt, Joaquim, Loriot, Yohann, Necchi, Andrea, Hoffman-Censits, Jean, Perez-Gracia, Jose Luis, Dawson, Nancy A, van der Heijden, Michiel S, Dreicer, Robert, Srinivas, Sandy, Retz, Margitta M, Joseph, Richard W, Drakaki, Alexandra, Vaishampayan, Ulka N, Sridhar, Srikala S, Quinn, David I, Durán, Ignacio, Shaffer, David R, Eigl, Bernhard J, Grivas, Petros D, Yu, Evan Y, Li, Shi, Kadel, Edward E, Boyd, Zachary, Bourgon, Richard, Hegde, Priti S, Mariathasan, Sanjeev, Thåström, AnnChristine, Abidoye, Oyewale O, Fine, Gregg D, Bajorin, Dean F
Yayımlandı Lancet (2016)